336 related articles for article (PubMed ID: 26599579)
21. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
[TBL] [Abstract][Full Text] [Related]
22. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
[TBL] [Abstract][Full Text] [Related]
23. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
24. [The decreased level of plasma carnitine in patients with epilepsy].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
[TBL] [Abstract][Full Text] [Related]
25. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
Verrotti A; Greco R; Morgese G; Chiarelli F
Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
[TBL] [Abstract][Full Text] [Related]
26. Blood ammonia level during valproic acid therapy.
Kugoh T; Yamamoto M; Hosokawa K
Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
Duman B; Can KC; Ağtaş-Ertan E; Erdoğan S; İlhan RS; Doğan Ö; Kumbasar H; Çamsarı UM
Gen Hosp Psychiatry; 2019; 59():67-72. PubMed ID: 31276904
[TBL] [Abstract][Full Text] [Related]
28. [Role of hyperammonemia in stuporous states induced by sodium valproate].
Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
[TBL] [Abstract][Full Text] [Related]
29. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Vossler DG; Wilensky AJ; Cawthon DF; Kraemer DL; Ojemann LM; Caylor LM; Morgan JD
Epilepsia; 2002 Feb; 43(2):154-9. PubMed ID: 11903461
[TBL] [Abstract][Full Text] [Related]
30. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Gerstner T; Buesing D; Longin E; Bendl C; Wenzel D; Scheid B; Goetze G; Macke A; Lippert G; Klostermann W; Mayer G; Augspach-Hofmann R; Fitzek S; Haensch CA; Reuland M; Koenig SA
Seizure; 2006 Sep; 15(6):443-8. PubMed ID: 16787750
[TBL] [Abstract][Full Text] [Related]
31. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Cheng M; Tang X; Wen S; Yue J; Wang H
Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
[TBL] [Abstract][Full Text] [Related]
32. Valproic Acid-Associated Hyperammonemia: A Systematic Review.
Wong YJ; Fan J; Wan A; Mihic T; Gnyra M
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):283-294. PubMed ID: 37126830
[TBL] [Abstract][Full Text] [Related]
33. Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Hosseini H; Shafie M; Shakiba A; Ghayyem H; Mayeli M; Hassani M; Aghamollaii V
Psychopharmacology (Berl); 2023 Jan; 240(1):149-156. PubMed ID: 36459199
[TBL] [Abstract][Full Text] [Related]
34. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
[TBL] [Abstract][Full Text] [Related]
35. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K
Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
[TBL] [Abstract][Full Text] [Related]
36. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia.
Zaccara G; Paganini M; Campostrini R; Moroni F; Valenza T; Messori A; Bartelli M; Arnetoli G; Zappoli R
Ther Drug Monit; 1985; 7(2):185-90. PubMed ID: 3927530
[TBL] [Abstract][Full Text] [Related]
37. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Smith KM; Britton JW; Hocker SE; Toledano M
Neurologist; 2021 May; 26(3):80-82. PubMed ID: 33942787
[TBL] [Abstract][Full Text] [Related]
38. Asymptomatic hyperammonemia in children treated with valproic acid.
Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
[No Abstract] [Full Text] [Related]
39. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Noai M; Soraoka H; Kajiwara A; Tanamachi Y; Oniki K; Nakagawa K; Ishitsu T; Saruwatari J
Acta Neurol Scand; 2016 Mar; 133(3):216-23. PubMed ID: 26223287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
